4//SEC Filing
Hubbard John W 4
Accession 0001104659-24-092933
CIK 0001261249other
Filed
Aug 25, 8:00 PM ET
Accepted
Aug 26, 5:30 PM ET
Size
5.4 KB
Accession
0001104659-24-092933
Insider Transaction Report
Form 4
Hubbard John W
Director
Transactions
- Disposition to Issuer
Common Stock
2024-08-26$1.52/sh−976$1,484→ 0 total
Footnotes (1)
- [F1]Upon the consummation of the merger (the "Merger") pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 25, 2024, by and among Agile Therapeutics, Inc. (the "Company"), Insud Pharma, S.L. ("Insud"), and Exeltis Project, Inc., a Delaware corporation and indirect, wholly owned subsidiary of Insud ("Merger Sub"), 976 shares of Common Stock were converted into the right to receive into the right to receive a cash payment of $1.52 (the "Merger Consideration") per share of Common Stock, for an aggregate of $1,484, equal to the product of (x) the Merger Consideration, multiplied by (y) the total number of shares of Common Stock owned by the reporting person
Documents
Issuer
AGILE THERAPEUTICS INC
CIK 0001261249
Entity typeother
Related Parties
1- filerCIK 0001622323
Filing Metadata
- Form type
- 4
- Filed
- Aug 25, 8:00 PM ET
- Accepted
- Aug 26, 5:30 PM ET
- Size
- 5.4 KB